https://www.selleckchem.com/products/mrtx1719.html
We developed CRAX2MACE, a new tool derived from clinical and SPECTmyocardial perfusion imaging (MPI)variables, to predict 2-year probability of major adverse cardiac event (MACE) comprising death, hospitalized acute myocardial infarction or coronary revascularization. Consecutive individuals with SPECTMPI2001-2008 had two-year MACE determined from population-based health services data. CRAX2MACE included age, sex, diabetes, recent cardiac hospitalization, pharmacologic stress, stress total perfusion deficit (TPD), ischemic (stress-rest
Like
Comment
Share
